...
首页> 外文期刊>Internal medicine. >Rituximab-induced Acute Thrombocytopenia in a Patient with Follicular Lymphoma: A Case Report and Review of the Literature
【24h】

Rituximab-induced Acute Thrombocytopenia in a Patient with Follicular Lymphoma: A Case Report and Review of the Literature

机译:利妥昔单抗诱导的滤泡性淋巴瘤患者急性血小板减少症:一例病例报告并文献复习

获取原文
           

摘要

Rituximab is a highly effective agent that is used in the treatment of B-cell lymphoma. Rituximab-induced acute thrombocytopenia is a rare side effect that has previously been reported in a small number of patients with malignant lymphoma; its mechanism is still unknown. We herein report the case of a 74-year old man who was diagnosed with follicular lymphoma and who developed severe acute thrombocytopenia the day after the administration of rituximab. Coagulation abnormality, which mimicked disseminated intravascular coagulation, also appeared. When physicians use rituximab to treat high-risk patients, the platelet count should be closely monitored to avoid possible adverse events.
机译:利妥昔单抗是用于治疗B细胞淋巴瘤的高效药物。利妥昔单抗诱导的急性血小板减少症是一种罕见的副作用,以前在少数恶性淋巴瘤患者中已有报道。其机制仍然未知。我们在此报告了一名74岁的男性患者的病例,该患者被诊断患有滤泡性淋巴瘤,并在服用利妥昔单抗的第二天发展为严重的急性血小板减少症。还出现了模仿弥散性血管内凝血的凝血异常。当医师使用利妥昔单抗治疗高危患者时,应密切监测血小板计数,以避免可能的不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号